Alembic Pharmaceuticals Limited reported its consolidated financial results for the first quarter ended 30th June 2026.
Financial Highlights for Q1 FY26
• Revenue from operations increased by 26% YoY to Rs.2150 Cr.
• Profit After Tax at Rs. 173 Cr, up 12% YoY
• EBITDA pre R&D increased to Rs. 523 Cr; margin stood at 24%
Commenting on the results, Mr. Pranav Amin, Managing Director, Alembic Pharmaceuticals Limited, said,
“We have started FY27 on a strong note, delivering broad-based growth across our businesses. Performance during the quarter was driven by healthy volume growth, successful new product launches and continued execution across key markets. The US business delivered strong momentum, and the rest of the markets also recorded steady growth. We remain focused on strengthening our product portfolio, advancing our pipeline and driving sustainable long-term growth.”
Operational Highlights
India Branded Business
• India Branded Business delivered 7% YoY growth, reaching Rs 642 Cr. in revenue for the quarter.
• Gynaecology, Gastrology and Ophthalmology have shown robust growth.
• Animal healthcare segment delivered encouraging performance during the quarter.
• 3 new products were introduced during the quarter.
International Business
• US Formulation grew by 49% to Rs. 778 Cr.
• 7 Launches in the US market during the quarter.
• Ex-US Generics grew by 17% to Rs. 383 Cr.
• 10 ANDA approvals received during the quarter
API Business
• API business grew by 33% to Rs. 346 Cr.
The summary of Revenue from Operations is as under:
| Particulars | Q1 FY26 | Q1 FY27 | % Change |
| Formulation | |||
| India | 599 | 642 | 7% |
| USA Ex- US | 523 328 | 778 383 | 49% 17% |
| API | 261 | 346 | 33% |
| Total | 1711 | 2150 | 26% |